U.S. markets closed

Aravive, Inc. (ARAV)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.0200-0.0700 (-1.71%)
At close: 4:00PM EDT

Aravive, Inc.

River Oaks Tower
Suite 1200 3730 Kirby Drive
Houston, TX 77098
United States
936 355 1910

Full Time Employees17

Key Executives

NameTitlePayExercisedYear Born
Dr. Gail F. McIntyre CH (ASCP), DABT, Ph.D.Pres, CEO & Director562.47kN/A1963
Mr. Vinay Shah MBAChief Financial Officer481.99kN/A1963
Dr. Raymond Tabibiazar M.D.Advisor75.2kN/AN/A
Dr. Reshma Rangwala M.D., Ph.D.Chief Medical Officer455.81kN/A1978
Dr. Jeffrey L. ClelandCo-FounderN/AN/A1965
Dr. Joshua Silverman Ph.D.Co-FounderN/AN/AN/A
Joseph T. SchepersVP of Investor RelationsN/AN/AN/A
Dr. Randy L. AndersonSr. VP of Data SciencesN/AN/AN/A
Kenneth L. GuernseySec.N/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases. Its lead product candidate is AVB-500, a decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase Ib/II clinical trial for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, HER negative breast cancer, uterine, pancreatic cancer, urothelial, and non-small-cell lung cancers. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a strategic collaboration agreement with WuXi Biologics to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain AVB-500 as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. is headquartered in Houston, Texas.

Corporate Governance

Aravive, Inc.’s ISS Governance QualityScore as of July 1, 2021 is 9. The pillar scores are Audit: 8; Board: 9; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.